NCT02728518

Nebulized Amikacin Versus Intravenous Amikacin in the Treatment of Nosocomial Pneumonia

Evaluation of the Safety and Efficacy of Nebulized Amikacin as Adjunctive Therapy in Hospital Acquired and Ventilator Associated Bacterial Pneumonia in Surgical Intensive Care Units

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 133 (actual)
• Sponsor: National Heart Institute, Egypt · Other Government
• Sex: All
• Age: 21 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The investigator's goal in this study is to evaluate the efficacy and safety of nebulized amikacin versus intravenous amikacin in patients with hospital and ventilator acquired pneumonia in surgical patients admitted to the intensive care units infected with gram negative bacilli

Detailed description

prospective, randomized, controlled study on post-cardiac surgery patients , included two groups, over one year period. The first group was administered intravenous (IV) amikacin 20 mg/kg once daily. The second group was prescribed amikacin nebulizer 400 mg twice daily. Both groups were co-administered intravenous (IV) piperacillin/tazobactam empirically.

Conditions

• Pneumonia

Interventions

Type	Name	Description
DRUG	Nebulized Amikacin	400mg twice daily nebulized amikacin
DRUG	Intravenous Amikacin	20mg/kg once daily intravenous amikacin

Timeline

• Start date: 2014-08-01
• Primary completion: 2015-08-01
• Completion: 2015-08-01
• First posted: 2016-04-05
• Last updated: 2016-08-25